US 11,773,070 B2
Dihydrooxadiazinones
Manuel Ellermann, Berlin (DE); Stefan Nikolaus Gradl, Berlin (DE); Charlotte Christine Kopitz, Falkenesee (DE); Martin Lange, Berlin (DE); Adrian Tersteegen, Wuppertal (DE); Philip Lienau, Berlin (DE); Christa Hegele-Hartung, Mülheim an der Ruhr (DE); Detlev Sülzle, Berlin (DE); Timothy A. Lewis, Cambridge, MA (US); Heidi Greulich, Cambridge, MA (US); Xiaoyun Wu, Cambridge, MA (US); Matthew Meyerson, Boston, MA (US); and Alex Burgin, Cambridge, MA (US)
Assigned to Bayer Aktiengesellschaft, Leverkusen (DE); Bayer Pharma Aktiengesellschaft, Berlin (DE); The Broad Institute, Inc., Cambridge, MA (US); and Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Filed by Bayer Aktiengesellschaft, Leverkusen (DE); Bayer Pharma Aktiengesellschaft, Berlin (DE); The Broad Institute, Inc., Cambridge, MA (US); and Dana-Farber Cancer Institute, Inc., Boston, MA (US)
Filed on Jul. 14, 2022, as Appl. No. 17/865,236.
Application 17/865,236 is a division of application No. 16/635,504, granted, now 11,427,553, previously published as PCT/EP2018/071039, filed on Aug. 2, 2018.
Claims priority of provisional application 62/541,627, filed on Aug. 4, 2017.
Prior Publication US 2022/0396554 A1, Dec. 15, 2022
Int. Cl. C07D 273/04 (2006.01); C07D 413/10 (2006.01); C07D 413/12 (2006.01); C07D 417/10 (2006.01); C07D 471/04 (2006.01); C07D 491/107 (2006.01); C07D 495/10 (2006.01)
CPC C07D 273/04 (2013.01) [C07D 413/10 (2013.01); C07D 413/12 (2013.01); C07D 417/10 (2013.01); C07D 471/04 (2013.01); C07D 491/107 (2013.01); C07D 495/10 (2013.01)] 9 Claims
 
1. A compound having the structure

OG Complex Work Unit Chemistry
(6S)-5-[4′-fluoro-2-(trifluoromethyl)biphenyl-4-yl]-6-methyl-3,6-dihydro-2H-1,3,4-oxadiazin-2-one,
or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, or a salt thereof, or a mixture of same.